Doug Cole, MD

Doug Cole, M.D., has served as a member of our Board of Directors since October 2015. An entrepreneur, investor, and physician, Doug plays an active role as a co-founder and initial chief executive officer of multiple Flagship companies, including Foghorn Therapeutics. Doug has a significant track record of board experience and currently serves on the board of directors of numerous public and private companies.

Included among the companies Doug has helped build are Agios Pharmaceuticals, Denali Therapeutics, Editas Medicine, Hypnion (acquired by Eli Lilly), Morphotek (acquired by Eisai), Quanterix, Receptos acquired by Celgene), and Syros Pharmaceuticals.

Doug is trained as a neurologist and completed his post-graduate training at the Johns Hopkins Hospital in Baltimore, MD, and the Massachusetts General Hospital, in Boston, MA. Prior to joining Flagship, Doug held medical posts at Harvard Medical School and the Massachusetts General Hospital, and he has also served as an executive at Cytotherapeutics and Vertex Pharmaceuticals.

Doug holds an A.B. magna cum laude with high distinction in English from Dartmouth College and an M.D. from University of Pennsylvania School of Medicine.